In-stent restenosis limitation with stent-based controlled-release nitric oxide: initial results in rabbits

Radiology. 2004 Feb;230(2):377-82. doi: 10.1148/radiol.2302020417. Epub 2003 Dec 29.

Abstract

Purpose: To evaluate effect of controlled stent-based release of an NO donor to limit in-stent restenosis in rabbits.

Materials and methods: Bioerodable microspheres containing NO donor or biodegradable polymer (polylactide-co-glycolide-polyethylene glycol) were prepared and loaded in channeled stents. Daily concentrations of NO release from NO-containing microspheres were assayed in vitro. NO- and polymer-containing (control) microsphere-loaded stents were deployed in aortas of New Zealand white rabbits (n = 8). Aortas with stents were harvested at 7 (n = 5) and 28 days (n = 3) and evaluated for cyclic guanosine monophosphate (cGMP) levels (7 days), number of proliferating cell nuclear antigen-positive cells (7 days), and intima-to-media ratio (7 and 28 days), with statistical significance evaluated by using one-way analysis of variance.

Results: NO-containing microspheres released NO with an initial bolus in the 1st week, followed by sustained release for the remaining 3 weeks. Significant increase in cGMP levels and decrease in proliferating cell nuclear antigen-positive cells were found at 7 days for the NO-treated group relative to controls (P <.05). Intima-to-media ratio in the NO-treated group was reduced by 46% and 32% relative to controls at 7 and 28 days, respectively (mean, 0.14 +/- 0.01 [standard error] vs 0.26 +/- 0.02 at 7 days, P <.01; 1.34 +/- 0.05 vs 1.98 +/- 0.08 at 28 days, P <.01).

Conclusion: Stent-based controlled release of NO donor significantly reduces in-stent restenosis and is associated with increase in vascular cGMP and suppression of proliferation.

MeSH terms

  • Angiography, Digital Subtraction
  • Animals
  • Aorta, Abdominal / pathology
  • Aortography
  • Arterial Occlusive Diseases / pathology*
  • Cell Division / drug effects
  • Coated Materials, Biocompatible*
  • Cyclic GMP / metabolism
  • Male
  • Microspheres
  • Muscle, Smooth, Vascular / drug effects*
  • Muscle, Smooth, Vascular / pathology
  • Nitric Oxide Donors / pharmacology*
  • Nitroso Compounds / pharmacology*
  • Prosthesis Failure
  • Rabbits
  • Secondary Prevention
  • Stents*

Substances

  • Coated Materials, Biocompatible
  • NOC 12
  • Nitric Oxide Donors
  • Nitroso Compounds
  • Cyclic GMP